Drug-Induced Maculopapular Rash Following Initiation of Anti-Tubercular Therapy: A Case Study

1. WHO. Treatment of Tuberculosis: Guidelines. 4th ed. World Health Organization; 2010.
2. Saukkonen JJ, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
3. Schaberg T, et al. Side effects of the antituberculosis drugs: Results of the German Thorax Center study. Eur Respir J. 1996;9(2):356–362.
4. Babalik A, et al. Management of cutaneous adverse drug reactions due to antituberculosis drugs. Int J Tuberc Lung Dis. 2012;16(6): 772–777.
5. Sharma SK, et al. Adverse reactions to anti-tuberculosis drugs & their management. Indian J Med Res. 2015;141(1):21–31.
6. Pirmohamed M, et al. Adverse drug reactions. BMJ. 2003; 329(7456): 15–19.
7. Yee D, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477.
8. Chuenchom N, et al. Management of cutaneous adverse drug reactions due to antituberculosis drugs: A review. J Dermatolog Treat. 2020;31(3): 1–8.
9. Tostmann A, et al. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202.
10. WHO-UMC. The use of the WHO-UMC system for standardised case causality assessment. Uppsala Monitoring Centre; 2018.